Covid19 Clinical Trial
— STEPCOOfficial title:
Short and Medium-term Effects of Pulmonary Rehabilitation in Mild to Critical Post-acute COVID-19 - an Observational Trial
Verified date | December 2021 |
Source | Schön Klinik Berchtesgadener Land |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
As a direct consequence of the COVID-19 pandemic, it is assumed that the number of patients with COVID-19-related disabilities will increase significantly. Patients with mild, severe, and critical forms of the disease show long-term sequelae in different systems (respiratory, muscular, psychological, cognitive etc.). Persistent dyspnea is a frequently described symptom after the acute phase of the disease. Coupled with reduced oxygen saturation, an increased risk of developing lung fibrosis has been observed. Specialized rehabilitation medicine (e.g. pulmonary rehabilitation) might counteract these long-term consequences and therefore seems to be a promising approach to treat long-term COVID-19 consequences. Further, there is scarce evidence about COVID-19 specific rehabilitation contents. It was suggested to use treatment regimes in analogy to patients with idiopathic pulmonary fibrosis. There is evidence that pulmonary rehabilitation improves physical performance, quality of life and reduces anxiety and depression symptoms in patients with idiopathic pulmonary fibrosis and other chronic respiratory diseases. Since impairments related to idiopathic pulmonary fibrosis also play an important role in COVID-19, the aim of this study is to evaluate the short and medium-term effects of a standardized 3-week pulmonary rehabilitation program. The results will be analyzed within the two cohorts (mild/moderate and severe/critical COVID 19) as well as between the two cohorts for the primary outcome. Furthermore, the effects of pulmonary rehabilitation will be compared with a retrospective cohort of idiopathic pulmonary fibrosis.
Status | Completed |
Enrollment | 50 |
Est. completion date | January 16, 2021 |
Est. primary completion date | January 16, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Post-acute phase COVID-19 patients with mild, moderate, severe or critical course - written informed consent Exclusion Criteria: - patients who are unable to walk |
Country | Name | City | State |
---|---|---|---|
Germany | Schön Klinik Berchtesgadener Land | Schönau Am Königssee | Bavaria |
Lead Sponsor | Collaborator |
---|---|
Schön Klinik Berchtesgadener Land |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in 6-minute walk distance | measure in meter | Day 1 and day 21 of pulmonary rehabilitation | |
Secondary | change in endurance shuttle walk distance | measure provided in seconds | Day 1 and day 21 of pulmonary rehabilitation | |
Secondary | Change in Diffusion capacity of the lungs for Carbon monoxide | measure provided in % predicted | Day 1 and day 21 of pulmonary rehabilitation | |
Secondary | Change in Forced Vital Capacity | measure provided in % predicted | Day 1 and day 21 of pulmonary rehabilitation | |
Secondary | Change in total lung capacity | measure provided in % predicted | Day 1 and day 21 of pulmonary rehabilitation | |
Secondary | change in Montreal cognitive assessment test | score ranges from 0 to 30 with lower score indicating higher cognitive impairment | Day 1 and day 21 of pulmonary rehabilitation | |
Secondary | change in short-form 36 question health survey | score ranges from 0 to 100 with higher scores indicating better Quality of life | Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitation | |
Secondary | change in Patient-Reported Outcomes Measurement Information System - 29 (PROMIS-29) | A questionnaire designed to measure self-reported physical, mental and social health and wellbeing. Higher scores represent worse symptomatology in relation to the mean value of 50 points with a standard deviation of 10 points. | Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitation | |
Secondary | Change in the scale of general anxiety disorder - 7 questionnaire (GAD-7) | score ranges from 0 to 21 with higher scores indicating more severe anxiety | Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitation | |
Secondary | Change in the scale of the patient health questionnaire - Depression (PHQ-D) | score ranges from 0 to 27 with higher scores indicating more severe depression | Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitation | |
Secondary | Change in prevalence of COVID-19 related dyspnea | patients will be asked if they still perceive COVID-19 related dyspnea: answer possibilities yes or no | Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitation | |
Secondary | Change in prevalence of COVID-19 related cough | patients will be asked if they still perceive COVID-19 related cough: answer possibilities yes or no | Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitation | |
Secondary | Change in prevalence of COVID-19 related cognitive impairment | patients will be asked if they still perceive COVID-19 related cognitive impairment: answer possibilities yes or no | Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitation | |
Secondary | Change in prevalence of COVID-19 related loss of appetite | patients will be asked if they still perceive COVID-19 related loss of appetite: answer possibilities yes or no | Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitation | |
Secondary | Change in general perceived well-being | scale from 1 (worst) to 10 (best) | Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitation | |
Secondary | change in D-Dimer level | in mg/l | Day 1 and day 21 of pulmonary rehabilitation | |
Secondary | change in c-reactive protein level | in mg/l | Day 1 and day 21 of pulmonary rehabilitation | |
Secondary | change in leukocytes level | in g/l | Day 1 and day 21 of pulmonary rehabilitation | |
Secondary | change in hemoglobin level | in g/dl | Day 1 and day 21 of pulmonary rehabilitation | |
Secondary | change in troponin level | in pg/ml | Day 1 and day 21 of pulmonary rehabilitation | |
Secondary | change in pro-brain natriuretic peptide level | in pg/ml | Day 1 and day 21 of pulmonary rehabilitation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |